OVERVIEW OF VZV STUDY DESIGN

Printer-friendly versionPDF version

This study aims to assess immunological aspects of Varicella-Zoster virus (VZV)

in preparation of its use as a vector for a future HIV vaccine. Twenty three

million Africans including 1.6 million Kenyans are infected with HIV, the causative

agent of acquired immune deficiency syndrome (AIDS). Despite global efforts to

control the spread of HIV, millions of new infections still occur annually. In

2012 alone there were 2.3 million new HIV infections worldwide, most of these

occurring in sub-Sahara Africa [1,2]. It is generally accepted that an effective

and accessible preventative HIV vaccine is the best hope for ending the AIDS

epidemic.

 

A protective HIV vaccine most likely will have to induce an effector HIV-specific

immune response at the mucosal site (the portal of entry of HIV), blocking the

spread of the virus to lymphoid tissues and controlling the infection at the

mucosal or tissue level [3,4]. HIV vaccine candidates to date have not been able

to induce such immune response; however, the use of a persistent replicating

viral vector has huge potential to assemble this specific response.  The only

persistent replicating virus currently approved to be used as a vaccine in humans

is Varicella-Zoster Virus (VZV), also known as chickenpox.

 

Attenuated varicella vaccines have been used worldwide for over 25 years

and have a well-described safety profile. The epidemiology of varicella differs

in temperate and tropical climates being more prevalent in the former one [5-7].

VZV infection is considered a childhood disease however, when the primary VZV

infection occurs at later ages, there is an increased risk of complications such

as lower respiratory infections, viral pneumonitis, and more rarely

encephalitis [8]. VZV infection imposes a special risk for

immunocompromised patients, representing an important cause of

morbidity and mortality in this population. The risks associated with VZV

infection in adulthood, especially in the HIV-positive individuals, justify the use

of this vaccine in tropical countries such as Kenya.

 

Although these vaccines have been widely used worldwide, there is a lack of

information on their immunogenicity in the African population. In this study we

aim to evaluate the immune response induced by the VZV-vaccine Zostavax®

in Kenya. A detailed analysis of the effector immune response and

immune activation profile at the mucosal tissues induced by VZV

vaccination in VZV-seropositive individuals is our primary goal. Understanding

these components is a key step in evaluating the potential of VZV as a vector in

an HIV vaccine.

AttachmentSize
VZV Study Design.doc54.5 KB
VZV Study Design.docx24.77 KB
VZV Study Design.pdf102.62 KB

Contacts

KAVI Institute of Clinical Research (KAVI-ICR)

College of Health Sciences

University of Nairobi

P.O. Box 19676 - 00202

Nairobi,

Kenya.

 

Telephone: +254-20-2717694/2725404

 

Mobile: +254-722-207417

 

Fax: +254-20-2714613

 

E-mail: kavi@kaviuon.org

 

Locate us>>

Community Outreach

Media Center

UoN Website | UoN Repository | ICTC Website


Copyright © 2017. ICT WebTeam, University of Nairobi